China Universal Asset Management Co. Ltd. Has $241,000 Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

China Universal Asset Management Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 64.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,317 shares of the company’s stock after buying an additional 2,879 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Tarsus Pharmaceuticals were worth $241,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Jennison Associates LLC acquired a new position in shares of Tarsus Pharmaceuticals during the first quarter worth approximately $48,380,000. Quantbot Technologies LP acquired a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at $410,000. Swiss National Bank grew its position in Tarsus Pharmaceuticals by 1.4% in the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after purchasing an additional 600 shares during the period. Sei Investments Co. increased its stake in Tarsus Pharmaceuticals by 128.2% during the 1st quarter. Sei Investments Co. now owns 32,804 shares of the company’s stock valued at $1,192,000 after purchasing an additional 18,426 shares in the last quarter. Finally, Thoroughbred Financial Services LLC acquired a new position in Tarsus Pharmaceuticals during the first quarter worth $762,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 2.0 %

TARS opened at $44.73 on Thursday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $13.90 and a fifty-two week high of $46.71. The firm has a market capitalization of $1.70 billion, a P/E ratio of -9.98 and a beta of 1.07. The company’s 50-day moving average is $33.15 and its 200 day moving average is $31.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million for the quarter, compared to analysts’ expectations of $31.30 million. During the same quarter last year, the firm earned ($1.17) EPS. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on TARS. Oppenheimer reissued an “outperform” rating and set a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $51.60.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.